Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyResearch in context
Summary: Background: Over the last decade, the development of innovative cancer treatments has accelerated and has been associated with improved mortality trends; however, local regulatory approval times are extensive. This study estimated the clinical and economic impact of delays in the approval...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | The Lancet Regional Health. Americas |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667193X25001826 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849710100119289856 |
|---|---|
| author | Andrés F. Cardona Natalia Sánchez Liliana Gutiérrez-Babativa Leonardo Rojas Jairo Zuluaga Stella Martínez Lucia Viola Carlos Carvajal Juliana Bogoya Laura Prieto-Pinto Daniel Samacá-Samacá Antonio Robles Joshua Kock Claudio Martín Luis Corrales Luis E. Raez Vladmir Cordeiro de Lima Suraj Samtani Oscar Arrieta |
| author_facet | Andrés F. Cardona Natalia Sánchez Liliana Gutiérrez-Babativa Leonardo Rojas Jairo Zuluaga Stella Martínez Lucia Viola Carlos Carvajal Juliana Bogoya Laura Prieto-Pinto Daniel Samacá-Samacá Antonio Robles Joshua Kock Claudio Martín Luis Corrales Luis E. Raez Vladmir Cordeiro de Lima Suraj Samtani Oscar Arrieta |
| author_sort | Andrés F. Cardona |
| collection | DOAJ |
| description | Summary: Background: Over the last decade, the development of innovative cancer treatments has accelerated and has been associated with improved mortality trends; however, local regulatory approval times are extensive. This study estimated the clinical and economic impact of delays in the approval of innovative therapies for the treatment of advanced lung cancer in men in five Latin American countries. Methods: Using public data, we estimated the relationship between available innovative therapies (AIT) and age-specific mortality rate (ASMR) for Argentina, Brazil, Chile, Colombia, and Mexico through a regression model. Based on the difference between the number of FDA-approved therapies and the number approved by each local agency, we calculated the avoidable deaths (ADs) if innovation had been available. We estimated the Years of Life Lost (YLLs) using the life expectancy, the median age of death, and the ADs. Productivity loss (PL) was calculated using each country’s retirement age and yearly Gross Domestic Product per capita (GDPc) in 2022 constant USD. Findings: Total ADs, YLLs, and PL were 8694, 114,477, and USD 439,179,876, respectively. Argentina had the highest impact of AIT on ASMR. Brazil’s results showed a high clinical and economic impact, primarily due to its large population. Chile’s high GDPc led to high PL. Colombia and Mexico showed a high clinical impact, suggesting a benefit of early approval. Differences in availability and approval times have increased with the number of FDA-approved therapies, yet local time gaps have recently increased. Interpretation: Our study shows the substantial clinical and economic impact of delays in approving innovative therapies, underscoring the potential of improving regulatory processes to increase the availability of lung cancer treatments. Accelerating the introduction of innovative therapies for advanced lung cancer in Latin America represents a significant opportunity to enhance survival rates, instilling hope and optimism while also avoiding substantial PL. Funding: This study was conducted as a research partnership between Roche and CTIC. No funding was received. Authors participated in the study design, data collection, data analysis, interpretation, and writing of the report. |
| format | Article |
| id | doaj-art-d3601d3044cd45f9a94de76f3b2c18ef |
| institution | DOAJ |
| issn | 2667-193X |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Americas |
| spelling | doaj-art-d3601d3044cd45f9a94de76f3b2c18ef2025-08-20T03:15:03ZengElsevierThe Lancet Regional Health. Americas2667-193X2025-09-014910117210.1016/j.lana.2025.101172Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyResearch in contextAndrés F. Cardona0Natalia Sánchez1Liliana Gutiérrez-Babativa2Leonardo Rojas3Jairo Zuluaga4Stella Martínez5Lucia Viola6Carlos Carvajal7Juliana Bogoya8Laura Prieto-Pinto9Daniel Samacá-Samacá10Antonio Robles11Joshua Kock12Claudio Martín13Luis Corrales14Luis E. Raez15Vladmir Cordeiro de Lima16Suraj Samtani17Oscar Arrieta18Institute of Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia; GIGA/TERA Research Groups (CTIC/Universidad El Bosque), Bogotá, Colombia; Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia; Corresponding author. Institute of Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Cra. 14 #169-49, Bogotá, Colombia.Institute of Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia; GIGA/TERA Research Groups (CTIC/Universidad El Bosque), Bogotá, ColombiaInstitute of Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia; GIGA/TERA Research Groups (CTIC/Universidad El Bosque), Bogotá, ColombiaGIGA/TERA Research Groups (CTIC/Universidad El Bosque), Bogotá, Colombia; Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, ColombiaGIGA/TERA Research Groups (CTIC/Universidad El Bosque), Bogotá, Colombia; Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, ColombiaGIGA/TERA Research Groups (CTIC/Universidad El Bosque), Bogotá, Colombia; Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, ColombiaGIGA/TERA Research Groups (CTIC/Universidad El Bosque), Bogotá, Colombia; Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, ColombiaGIGA/TERA Research Groups (CTIC/Universidad El Bosque), Bogotá, Colombia; Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, ColombiaClinical Oncology Unit, Instituto Nacional de Cancerología – INC, Bogotá, ColombiaEvidence Generation Team, Roche Colombia, Bogotá, ColombiaEvidence Generation Team, Roche Colombia, Bogotá, Colombia; Corresponding author. Evidence Generation, Roche Colombia, Cra. 14 #93-68, Bogotá, Colombia.Evidence Generation Team, Roche Colombia, Bogotá, ColombiaEvidence Generation Team, Roche Colombia, Bogotá, ColombiaThoracic Oncology Unit, Instituto Alexander Fleming, Buenos Aires, ArgentinaMedical Oncology Unit, Centro de Investigación y Manejo del Cáncer (CIMCA), San José, Costa RicaThoracic Oncology Department, Memorial Cancer Institute, Memorial Health Care System, Florida Atlantic University (FAU), Miami, FL, United StatesThoracic Oncology Reference Center, A.C. Camargo Cancer Center, São Paulo, BrazilClínica las Condes Cancer Center, Santiago de Chile, ChileThoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, MexicoSummary: Background: Over the last decade, the development of innovative cancer treatments has accelerated and has been associated with improved mortality trends; however, local regulatory approval times are extensive. This study estimated the clinical and economic impact of delays in the approval of innovative therapies for the treatment of advanced lung cancer in men in five Latin American countries. Methods: Using public data, we estimated the relationship between available innovative therapies (AIT) and age-specific mortality rate (ASMR) for Argentina, Brazil, Chile, Colombia, and Mexico through a regression model. Based on the difference between the number of FDA-approved therapies and the number approved by each local agency, we calculated the avoidable deaths (ADs) if innovation had been available. We estimated the Years of Life Lost (YLLs) using the life expectancy, the median age of death, and the ADs. Productivity loss (PL) was calculated using each country’s retirement age and yearly Gross Domestic Product per capita (GDPc) in 2022 constant USD. Findings: Total ADs, YLLs, and PL were 8694, 114,477, and USD 439,179,876, respectively. Argentina had the highest impact of AIT on ASMR. Brazil’s results showed a high clinical and economic impact, primarily due to its large population. Chile’s high GDPc led to high PL. Colombia and Mexico showed a high clinical impact, suggesting a benefit of early approval. Differences in availability and approval times have increased with the number of FDA-approved therapies, yet local time gaps have recently increased. Interpretation: Our study shows the substantial clinical and economic impact of delays in approving innovative therapies, underscoring the potential of improving regulatory processes to increase the availability of lung cancer treatments. Accelerating the introduction of innovative therapies for advanced lung cancer in Latin America represents a significant opportunity to enhance survival rates, instilling hope and optimism while also avoiding substantial PL. Funding: This study was conducted as a research partnership between Roche and CTIC. No funding was received. Authors participated in the study design, data collection, data analysis, interpretation, and writing of the report.http://www.sciencedirect.com/science/article/pii/S2667193X25001826Lung neoplasmsDrug approvalInnovate therapiesLatin America |
| spellingShingle | Andrés F. Cardona Natalia Sánchez Liliana Gutiérrez-Babativa Leonardo Rojas Jairo Zuluaga Stella Martínez Lucia Viola Carlos Carvajal Juliana Bogoya Laura Prieto-Pinto Daniel Samacá-Samacá Antonio Robles Joshua Kock Claudio Martín Luis Corrales Luis E. Raez Vladmir Cordeiro de Lima Suraj Samtani Oscar Arrieta Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyResearch in context The Lancet Regional Health. Americas Lung neoplasms Drug approval Innovate therapies Latin America |
| title | Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyResearch in context |
| title_full | Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyResearch in context |
| title_fullStr | Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyResearch in context |
| title_full_unstemmed | Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyResearch in context |
| title_short | Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyResearch in context |
| title_sort | clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in latin america a population based secondary data studyresearch in context |
| topic | Lung neoplasms Drug approval Innovate therapies Latin America |
| url | http://www.sciencedirect.com/science/article/pii/S2667193X25001826 |
| work_keys_str_mv | AT andresfcardona clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT nataliasanchez clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT lilianagutierrezbabativa clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT leonardorojas clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT jairozuluaga clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT stellamartinez clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT luciaviola clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT carloscarvajal clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT julianabogoya clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT lauraprietopinto clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT danielsamacasamaca clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT antoniorobles clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT joshuakock clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT claudiomartin clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT luiscorrales clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT luiseraez clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT vladmircordeirodelima clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT surajsamtani clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext AT oscararrieta clinicalandeconomicimpactoftheavailabilityofinnovativetherapiesforadvancedlungcancerinmeninlatinamericaapopulationbasedsecondarydatastudyresearchincontext |